Can co‑amoxiclav (amoxicillin‑clavulanate) be used to treat leptospirosis, and what is the recommended dosing and indications?

Co-amoxiclav is NOT a standard or recommended treatment for leptospirosis

Co-amoxiclav (amoxicillin-clavulanate) should not be used as first-line therapy for leptospirosis. While amoxicillin alone has demonstrated efficacy against Leptospira species, there is no evidence supporting the use of the combination formulation with clavulanate for this indication, and standard treatment guidelines recommend other antibiotics.

Evidence-Based Treatment Recommendations

First-Line Antibiotics for Leptospirosis

The most robust evidence supports the following antibiotics:

For mild to moderate leptospirosis:

• Doxycycline is the preferred oral agent 1, 2, 3
  • Dosing: 100 mg twice daily for 7 days
  • Demonstrated significant reduction in defervescence time (MD -1.53 days) 1

For severe leptospirosis:

• Ceftriaxone or Cefotaxime are preferred parenteral agents 1, 3

  • Ceftriaxone showed the best efficacy profile with MD -1.22 days for defervescence 1
  • Cefotaxime demonstrated even better results (MD -1.88 days) 1

• Penicillin G (intravenous) is an alternative for severe cases 1, 2

Why Amoxicillin (Without Clavulanate) Has Limited Support

While older studies from 1976 demonstrated that amoxicillin alone (not co-amoxiclav) had leptospirocidal activity 4, 5, this evidence is:

• Extremely dated (nearly 50 years old)
• Based on small patient numbers (28 patients total)
• Not replicated in modern systematic reviews

Recent in vitro susceptibility testing confirms that Leptospira isolates remain susceptible to amoxicillin 6, but the addition of clavulanate provides no theoretical benefit since Leptospira does not produce beta-lactamases.

Clinical Algorithm for Antibiotic Selection

Assess disease severity:

1. Mild disease (outpatient, no organ dysfunction):

   • Start doxycycline 100 mg PO twice daily × 7 days
   • Alternative: azithromycin (MD -1.74 days for defervescence) 1

2. Moderate disease (hospitalized, stable):

   • Doxycycline 100 mg PO/IV twice daily × 7 days
   • Or penicillin if doxycycline contraindicated

3. Severe disease (organ failure, jaundice, renal dysfunction):

   • Ceftriaxone 1-2g IV daily × 7-14 days 1, 3
   • Or cefotaxime 1g IV every 6-8 hours
   • Consider adding doxycycline for combination therapy in critically ill patients 3

Critical Pitfalls to Avoid

• Do not use co-amoxiclav simply because it's a broad-spectrum agent—it lacks specific evidence for leptospirosis and the clavulanate component is unnecessary
• Do not delay treatment waiting for serological confirmation; start empiric therapy based on clinical suspicion in endemic areas
• Do not use fluoroquinolones as first-line agents—they lack robust evidence in leptospirosis despite activity against other spirochetes
• Avoid macrolides as monotherapy in severe disease—reserve for mild cases or as alternatives when first-line agents are contraindicated

Evidence Quality Assessment

The 2024 systematic review and network meta-analysis 1 provides the highest quality evidence, analyzing 920 patients across multiple studies. This demonstrates that cephalosporins (cefotaxime, ceftriaxone), doxycycline, and penicillin significantly reduce defervescence time, while no evidence exists for co-amoxiclav specifically.

The FDA labeling for amoxicillin-clavulanate 7 lists approved indications as respiratory tract infections, otitis media, sinusitis, skin infections, and urinary tract infections caused by beta-lactamase-producing organisms—leptospirosis is not an approved indication.

If you must use a beta-lactam for leptospirosis due to contraindications to other agents, use amoxicillin alone (not the combination with clavulanate) at high doses (1g three times daily), recognizing this is based on limited historical data 4.